Q2 2025 Merit Medical Systems Inc Earnings Call Transcript

Jul 30, 2025 / 09:00 PM GMT

Release Date Price: €72 (+0.70%)

Transcript 10-Q8-K

Key Points

Positve

Merit Medical Systems Inc (MMSI) reported a 13% year-over-year increase in total revenue, reaching $382.5 million, exceeding expectations.
The company achieved a record high non-GAAP operating margin of 21.2%, marking a significant improvement of 109 basis points year-over-year.
Merit Medical Systems Inc (MMSI) generated $70 million in free cash flow, representing a 20% increase year-over-year.
The acquisition of Biolife Delaware LLC is expected to enhance the company's product offerings and tap into a $350 million global addressable market.
The company has updated its 2025 financial guidance, projecting GAAP net revenue growth of 10% to 11% year-over-year, with strong growth expected in both cardiovascular and endoscopy segments.

Negative

Merit Medical Systems Inc (MMSI) faced a two-quarter delay in securing add-on reimbursement for the Rhapsody CIE in the outpatient setting, impacting revenue expectations.
The company experienced a 6% decrease in sales in China, attributed to the broader macro environment, which was below expectations.
There was a misunderstanding in the reimbursement application process for the Rhapsody CIE, leading to a delay in securing the anticipated APC assignment.
The company is facing challenges related to tariffs, with potential impacts on costs and profitability, although efforts are being made to mitigate these effects.
Despite strong overall performance, the OEM product sales were modestly lower than expected, particularly outside the US, due to macroeconomic factors.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MMSI.OQ - Merit Medical Systems Inc
Q2 2025 Merit Medical Systems Inc Earnings Call
Jul 30, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Merritt Medical System's 2nd quarter 2025 earnings conference call. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Mr. Fred Lampropoulos, Merritt Medical Systems, founder, Chairman and Chief Executive Officer. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you and welcome everyone. I am joined on the call today by Raul.

--

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.